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550 Abstracts August 2013compared outcomes for AVFs and AVGs in patients with equivalent vascular
anatomy who were also receiving dialysis through a catheter at the time of
vascular access placement. Patients who underwent a ﬁrst-time AVF or AVG
between 2006 and 2009, who were on dialysis through a catheter at the
time of access placement, and who had favorable arterial and venous
anatomy (>3 mm) were compared. The study included 89 AVFs and 59
AVG patients who met study inclusion criteria. Similar secondary patency
was achieved by AVGs and AVFs at 12 months (72% vs 71%) and 24 months
(57% vs 62%), respectively (P ¼ .96). Interventions required to maintain
patency for AVFs (n ¼ one; range, zero-10) and AVGs (n ¼ one; range,
zero-11) were not different (P ¼ .36). The number of catheter days to ﬁrst
access use was more than doubled in the AVF group (mean, 81 days)
compared with the AVG group (mean, 38 days; P < .001).
Comment: This is a relatively small retrospective single-center study
and, as the authors point out, cannot be used to conclude outcomes for
AVFs and AVGs are equivalent. Nor should we conclude from this report
that efforts to increase the prevalence of AVFs vs AVGs should cease.
Rather, the study points out that in speciﬁc patient populations, under
very speciﬁc circumstances, blind adherence to the principals of the Fistula
First Initiative may actually be detrimental for patients. What are needed
are evidence-based algorithms for hemodialysis access in the patient
requiring renal replacement therapy. Such algorithms need to take into
account a multitude of variables that effect maturation and patency of
AVFs. Perhaps a risk factor-based predictive model of outcomes for AVFs
could be developed that is methodologically similar to the one purposed
for carotid endarterectomy by Bekelis et al, also featured in this abstract
section of the Journal.Association of Perioperative b-Blockade With Mortality and
Cardiovascular Morbidity Following Major Noncardiac Surgery
London MJ, Hur K, Schwartz GG, et al. JAMA 2013;309:1704-13.
Conclusion: Among propensity-matched patients undergoing
noncardiac, nonvascular surgery, perioperative b-blocker exposure was asso-
ciated with lower rates of 30-day all-cause mortality in patients with two or
more Revised Cardiac Risk Index factors. No association between b-blocker
exposure and outcome in patients undergoing vascular surgery could be
demonstrated.
Summary: Current class I recommendations of the American Heart
Association/American College of Cardiology Foundation Guidelines on
Perioperative Evaluation and Care for Noncardiac Surgery with respect to
b-blockers remain limited to continuation of pre-existing b-blocker therapy
(Fleisher LA et al, Circulation 2009;120:e169-276). Studies addressing the
use of perioperative b-blockade for noncardiac surgery differ with respect to
whether in-hospital perioperative b-blockade can reduce cardiovascular
events in patients undergoing noncardiac surgery. In addition, recent
evidence suggests the use of perioperative b-blockade may be declining
(Wijeysundera DN, Circ Cardiovasc Qual Outcomes 2012;5:558-65).
This perhaps reﬂects recent studies questioning the efﬁcacy of long-term
b-blockade in the stable outpatient (Devereaux PJ et al, Lancet
2008;371:1839-47). Given recent trends in downward use of b-blockade,
the authors sought to determine early perioperative outcomes with and
without early perioperative exposure to b-blockers by using 30-day postop-
erative outcomes in patients undergoing noncardiac surgery. This retrospec-
tive cohort analysis evaluated exposure to b-blockers on the day of or after
major noncardiac surgery. The study was a population-based sample of
136,745 patients who were 1:1 matched on propensity scores (37,805
matched pairs) and who were treated at 104 Department of Veterans Affairs
medical centers from January 2005 through August 2010. The main
outcome measure was all cause 30-day mortality and cardiac morbidity
(cardiac arrest or Q-wave myocardial infarction). Overall 55,138 patients
(40.3%) were exposed to b-blockers. Vascular surgical patients had the high-
est b-blocker exposure, 67.7% of 13,863 patients undergoing vascular
surgery (95% conﬁdence interval [CI], 65.9%-67.5%). Of the 122,882
patients undergoing nonvascular surgery, b-blocker exposure was 37.4%
(95% CI, 37.1%-37.6%; P < .001). With increasing numbers of Revised
Cardiac Risk Index factors, b-blocker exposure increased: 25.3% (95% CI,
24.9%-25.6%) in those with no risk factors vs 71.3% (95% CI, 69.5%-
73.2%) in those with four or more risk factors (P < .001). Death occurred
among 1.1% and cardiac morbidity among 0.9% of patients. In the propen-
sity-matched cohort, b-blocker exposure was associated with lower
mortality (relative risk [RR], 0.73; 95% CI, 0.65-0.83; P < .001; number
needed to treat [NNT], 241; 95% CI, 173-397). When stratiﬁed by cumu-
lative numbers of Revised Cardiac Risk Index factors, b-blocker exposure
was associated with signiﬁcantly lower mortality among patients with two
factors (RR, 0.63; P < .001; NNT, 105), three factors (RR, 0.54; P <
.001; NNT, 41), or four factors or more (RR, 0.40; P < .001; NNT,
18). b-blocker exposure was also associated with a lower rate of nonfatalQ-wave infarction or cardiac arrest (RR, 0.67; P < .001; NNT, 339). No
association could be demonstrated between b-blocker exposure and
outcomes in vascular surgical patients with respect to mortality at 30 days
and cardiac morbidity.
Comment: Among patients undergoing noncardiac surgery, vascular
surgery patients are generally considered at the highest risk of mortality
and cardiac morbidity. However, in this large and well-performed analysis,
b-blocker exposure did not inﬂuence outcomes in vascular surgical patients.
This may relate to a relatively small sample size compared with the nonvas-
cular surgical cohort or to the possibility patients received medications not
captured by the electronic database that was analyzed. In addition, vascular
surgical patients may have received a higher level of postoperative care (inten-
sive care unit utilization) than nonvascular patients. The American Heart
Association/American College of Cardiology Foundation recommendation
to continue perioperative b-blockade in patients undergoing noncardiac
vascular surgery who are already taking b-blockers seems reasonable. Unfor-
tunately, this study does not indicate the potential beneﬁt of new institution
of perioperative b-blockade in patients undergoing vascular surgery.Inﬂammation in Complex Regional Pain Syndrome: A Systematic
Review and Meta-Analysis
Parkitny L, McAuley JH, Di Pietro F, et al. Neurology 2013;80:106-17.
Conclusions: Complex regional pain syndrome (CRPS) is associated
with a proinﬂammatory state in blood, blister ﬂuid, and cerebral spinal ﬂuid
(CSF). Acute and chronic cases have different inﬂammatory proﬁles.
Summary: Clinically, CRPS is characterized by allodynia, severe pain,
hyperalgesia, and autonomic signs and symptoms (Marinus J et al, Lancet
Neurol 2011;10:637-48). The precise underlining mechanisms resulting
in CRPS are unknown; however, a number of studies have suggested an
inﬂammatory state of some sort characterizes both acute and chronic
CRPS (Huygen FJ et al, Immunol Lett 2004;91:147-154; and Groenweg
JG et al, BMC Musculoskelet Disord 2006;7:91). Identiﬁcation of speciﬁc
inﬂammatory modulators in acute and chronic forms of CRPS could guide
therapy to modify speciﬁc inﬂammatory states and, potentially, improve
CRPS symptoms. The authors therefore conducted a systematic review
and meta-analysis to determine whether CRPS is associated with a speciﬁc
inﬂammatory proﬁle. They also sought to determine whether such an
inﬂammatory proﬁle might be dependent on duration of the condition. A
comprehensive search of the literature using online databases was per-
formed. Articles that measured inﬂammatory factors in CRPS were identi-
ﬁed. Two independent investigators screened titles and abstracts and also
performed data extraction and risk of bias assessments. Studies were group-
ed by medium of ﬂuid analyzed (blood, blister ﬂuid, and CSF) and duration
of the CRPS condition (acute vs chronic). When possible, meta-analysis of
inﬂammatory factor concentrations was performed. Pooled effect sizes were
calculated using random-effects models. The authors identiﬁed 22 studies
for the systematic review and included 15 in the meta-analysis. In acute
CRPS, the concentration of interleukin (IL)-8 and soluble tumor necrosis
factor receptors I and II were increased signiﬁcantly in blood. In chronic
CRPS, there were (1) signiﬁcant increases in tumor necrosis factor-a, brady-
kinin, soluble (s)IL-IRI, IL-IRa, IL-2, sIL-2Ra, IL-4, IL-7, interferon-g,
monocyte chemoattractant protein-1, and soluble receptor for advanced
glycation end products in blood; (2) IL-IRa, monocyte chemoattractant
protein-I, macrophage inﬂammatory protein-Ib, and IL-6 in blister ﬂuid;
and (3) IL-Ib and IL-6 in CSF. Chronic CRPS was also associated with
signiﬁcantly decreased substance P, sE-selectin, sL-selectin, sP-selectin,
and sGPI30 in blood. There were also decreased levels of soluble intercel-
lular adhesion molecule-I in CSF.
Comment: The ﬁndings indicated that CRPS is associated with
a proinﬂammatory state both acutely and chronically. In addition, the
inﬂammatory states differ in the acute and chronic phase of CRPS. Sympa-
thectomy is often considered in the management of CRPS, but long-term
results are inconsistent. The data suggest that medical management of
CRPS targeting speciﬁc proinﬂammatory states has potential therapeutic
efﬁcacy. Whether this potential translates into clinical efﬁcacy or could be
combined with sympathectomy to improve management of CRPS will
require additional investigation.Blood Transfusion for Lower Extremity Bypass Is Associated with
Increased Wound Infection and Graft Thrombosis
Tze-Woei T, Farber A, Hamburg NM, et al., Vascular Study Group of New
England. JAMA 2013;216:1005-14.
Conclusion: Transfusion perioperatively in patients undergoing lower
extremity bypass (LEB) is associated with increased perioperative graft
thrombosis and wound infection.
